Richard Gorlick, MD


Dr. Gorlick on the Challenges of Identifying Immunotherapeutic Targets in Osteosarcomas

Richard Gorlick, MD, discusses the challenges of identifying immunotherapeutic targets in osteosarcomas.

Alice Indini, MD


Dr. Indini on the Rationale for the PULSAR Trial in Classic Kaposi Sarcoma

Alice Indini, MD, discusses the rationale for the phase 2 PULSAR trial in classic Kaposi sarcoma.

Ghaith Abu-Zeinah, MD


Dr. Abu-Zeinah on the Efficacy of Interferon-Alpha in Polycythemia Vera

Ghaith Abu-Zeinah, MD, discusses the efficacy of interferon-alpha in polycythemia vera.

City of Hope


City of Hope Appoints Marcel van den Brink, MD, PhD, As President of City of Hope Los Angeles and National Medical Center, and Chief Physician Executive

City of Hope announced the appointment of Marcel van den Brink, MD, PhD, as president of City of Hope Los Angeles and National Medical Center, chief physician executive and the Deana and Steve Campbell Chief Physician Executive Distinguished Chair in honor of Alexandra Levine, MD.

Grace Dy, MD


Dr. Dy on the Use of Sotorasib in KRAS G12C–Mutated NSCLC

Grace Dy, MD, discusses the use of sotorasib in patients with non–small cell lung cancer with KRAS G12C mutations.

Memorial Sloan Kettering Cancer Center


Memorial Sloan Kettering Cancer Center Launches MSKCC India to Expand Access to World-Renowned Oncologists, Cancer Care, Research, and Education

Memorial Sloan Kettering Cancer Center, the world’s oldest and largest private cancer center, has launched MSKCC India to provide cancer patients in India with access to the institution’s world-renowned oncologists, research, clinical trials, and education.

Rachel Zeig-Owens, DrPH, MPH


New Cancer Study Results Confirm Lasting Effects on 9/11 First Responders

Research investigating the physical and mental health consequences of being at the World Trade Center site during and after the terrorist attacks has been instrumental in obtaining health care coverage for thousands of individuals.

Brittany F. Lees, MD


Dr. Lees on the Utility of Genetic Testing in Ovarian Cancer

Brittany F. Lees, MD, discusses the utility of genetic and genomic testing in ovarian cancer.

Pratibha Binder, MD


Dr. Binder on the Use of Immune Checkpoint Inhibitors in Endometrial Cancer Treatment

Pratibha Binder, MD, discusses how the introduction of novel immune checkpoint inhibitors into frontline treatment strategies could ameliorate unmet needs in endometrial cancer.

Alessandro Gronchi, MD


Dr. Gronchi on the Results of the TRASTS Trial in Soft Tissue Sarcoma

Alessandro Gronchi, MD, discusses ​the results of the ​phase 2 TRASTS trial in soft tissue sarcoma.

Daniel Keifenheim, PhD


Novel Tubulin-Targeting Therapies Make Headway

Clinical findings have recently been reported for 2 of the more advanced emerging tubulin-targeting agents, VERU-111 and plinabulin.

Kent Hoskins, MD


Dr. Hoskins on the Impact of Race on Breast Cancer Outcomes

Kent Hoskins, MD, discusses the impact of race on breast cancer outcomes.

Emily C. Ayers, MD


Dr. Ayers on the Evolving Treatment Landscape in CLL

Emily C. Ayers, MD, hematologist​/oncologist​, assistant professor, University of Virginia Health, discusses the evolving treatment landscape in chronic lymphocytic leukemia.

Brian C. Grieb, MD, PhD


Dr Grieb on the Need for Novel Biomarkers in CRC

Brian C. Grieb, MD, PhD, discusses unmet needs for patients with colorectal cancer, including the identification of novel pan-CRC biomarkers for drug development.

Jeffrey Laurence, MD, Weill Cornell Medicine


Narsoplimab Trial Results

The panel of transplant experts discuss the results of the phase 2 trial of narsoplimab and the pending FDA approval of this agent for treatment of transplant-associated of thrombotic microangiopathy.

John P. Sfakianos, MD


Dr. Sfakianos on Importance of Restaging Transurethral Resection of Bladder Tumors

John P. Sfakianos, MD, discusses the importance of restaging transurethral resection of bladder tumors.

Aatur D. Singhi, MD, PhD


Dr. Singhi on the Importance of Multidisciplinary Care With Pathologists in Cancer

Aatur D. Singhi, MD, PhD, discusses the importance of facilitating multidisciplinary conversations that include pathologists in cancer care.

Lacey J. Padrón, PhD


Dr. Padrón on Biosignatures Found from a Phase 2 Study in Pancreatic Cancer

Lacey J. Padrón, PhD, discusses biosignatures found in a phase 2 study in pancreatic cancer.

Matthew J. Ehrhardt, MD, MS


Dr. Ehrhardt on Factors Associated with Late Mortality in Survivors of Childhood Cancer

Matthew J. Ehrhardt, MD, MS, discusses the link between modifiable chronic health conditions and social determinants of health with late mortality for survivors of childhood cancer.

Sarah Lang, MD, MBA


Dr. Lee on the Association of MSI-H, dMMR, and TMB-H Features in Endometrial Cancer

Sarah Lee, MD, MBA, discusses the association of microsatellite instability–high, mismatch repair deficiency, and tumor mutational burden–high features in endometrial cancer.

Joseph Mikhael, MD


Final Thoughts on Case Study and Treating Multiple Myeloma

Dr Joseph Mikhael and expert panel re-visit the patient case and offer their final thoughts on the impact of clinical trial updates in the treatment landscape of multiple myeloma.

Michael Wagner, MD


Dr Wagner or the Potential Value of Immunotherapy in Angiosarcoma

Michael J. Wagner, MD, explains how immunotherapy may be a promising treatment approach for patients with angiosarcoma.

Carmelo Carlo-Stella, MD, PhD


Dr Carlo-Stella on the FDA Approval of Glofitamab in Relapsed/Refractory DLBCL

Carmelo Carlo-Stella, MD, PhD, discusses the FDA approval of glofitamab for the treatment of patients with relapsed/refractory diffuse large B-cell lymphoma not otherwise specified or large B-cell lymphoma arising from follicular lymphoma, after at least 2 lines of systemic therapy.

William Gradishar, MD, Northwestern Medicine


Dr. Gradishar on the Significance of Drug Development in HER2+ Breast Cancer

William Gradishar, MD, discusses the significance of drug development in HER2-positive breast cancer.

Tucker Coston, MD


Dr. Coston on the Investigation of Bone Metastases in Neuroendocrine Neoplasms

Tucker Coston, MD, discusses the investigation of bone metastases in patients with well-differentiated neuroendocrine neoplasms using gallium-68 DOTATATE positron emission tomography scans.

Julie Collins, MD, MedStar Georgetown University Hospital


Dr. Collins on the Rationale for CDK4/6 Inhibitors in ER+ Breast Cancer

Julie M. Collins, MD, MPH, discusses the rationale for CDK4/6 inhibitors in endocrine receptor-positive breast cancer.

Jerome Zacks, MD


Advice for Community Physicians Treating Patients with Neuroendocrine Tumor-Associated Carcinoid Syndrome

Drs Das, Pommier, and Zacks share their advice for community physicians treating patients who have neuroendocrine tumors with carcinoid syndrome and carcinoid heart disease.

Jordan Hansford, MD


Dr Hansford on the FIREFLY-1 Trial of Tovorafenib in Pediatric Low-Grade Glioma

Jordan Hansford, MD, discusses the phase 2 FIREFLY-1 trial, which is investigating the pan-RAF inhibitor tovorafenib (DAY101) in children and young adults with low-grade glioma.

Sarah Nagle, MD


Dr. Nagle on Investigational Cellular Therapies in Multiple Myeloma

Sarah Nagle, MD, assistant professor of medicine, School of Medicine, Oregon Health & Science University, discusses investigational cellular therapies in multiple myeloma.